Screening for antidiabetic activities.

Area of Science:

• Pharmacology and Toxicology
• Endocrinology and Metabolism

Background:

• Screening antidiabetic compounds is primarily conducted in animal models due to the multi-organ involvement in hyperglycemia and diabetes complications.
• In vitro findings often lack direct correlation with in vivo outcomes, particularly for complex diseases like Diabetes Mellitus.
• Animal models, both genetically manipulated and chemically induced, are vital for understanding disease pathogenesis and individual contributions.

Purpose of the Study:

• To review the utility and limitations of animal models in screening antidiabetic drug entities.
• To highlight the challenges in translating in vitro results to in vivo efficacy for diabetes treatment.
• To discuss the role of various animal models in studying Type I and Type II diabetes pathogenesis.

Main Methods:

• Utilizing diverse animal models, including spontaneous, induced, and transgenic, to mimic aspects of diabetes.
• Employing both normoglycemic and diabetic animal subjects for drug efficacy assessment.
• Measuring key biomarkers such as blood glucose and insulin levels to evaluate antidiabetic activity.

Main Results:

• A wide array of animal models exists for studying diabetes, yet an ideal, standardized model for all antidiabetic drug classes remains elusive.
• Rodents (rats and mice) are commonly used, with both healthy and diabetic states employed for testing.
• Biomarker analysis, including blood glucose and insulin, provides essential data for assessing drug effects.

Conclusions:

• Specialized animal models facilitate research into the genetic and biochemical factors influencing diabetes pathogenesis.
• Despite the availability of numerous models, a universal standard for evaluating individualized antidiabetic drug effects is lacking.
• Continued use of varied animal models and biomarker analysis is essential for advancing antidiabetic drug discovery.